Glen Rock, N.J., June 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present…
Glen Rock, N.J., May 16, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its March 31, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
Use of Ampakines as a Novel Therapy for Overcoming Central Respiratory Depression Glen Rock, N.J., April 1, 2016/Globe Newswire ? RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (?RespireRx? or the ?Company?), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, is providing an update on the Company?s collaborative research…
Provides Update on Current Operations and Plans for 2016 Glen Rock, N.J., March 29, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its December 31, 2015 Annual Report on Form 10-K and…
Glen Rock, N.J., March 11, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President and CEO, and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will…
Glen Rock, N.J., Feb. 29, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI as of January 11, 2016; previously OTC QB: CORX) (“RespireRx” or the “Company”), a leader in developing medicines for respiratory disorders, particularly sleep apnea and drug-induced respiratory depression, announced today that it has received notice that the U.S. Food and Drug…
Glen Rock, N.J., February 4, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the developent of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announces that the Company’s President & CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will…
RespireRx Expands Research Initiatives Involving Treatments for Drugs of Abuse Glen Rock, N.J., January 19, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) announces that the Company has reached an agreement with the Medications Development Program of the National Institute of Drug Abuse (“NIDA”) for NIDA to conduct research on RespireRx…
Glen Rock, N.J., January 19, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that the Company’s Vice President, Treasurer and Secretary and member of the Board of Directors, Jeff Margolis will present at the…
CEO to Review Initiatives in the Treatment of Respiratory Disorders and Provide Pipeline Update RespireRx Announces Ticker Symbol Change Glen Rock, N.J., Jan. 11, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI as of January 11, 2016; previously OTC QB: CORX) (“RespireRx” or the “Company”), a leader in developing drugs for respiratory disorders, particularly…